SEPN Septerna Inc
QT65| Index | — | P/E | — | EPS (ttm) | -0.54 | Insider Own | 39.14% | Shs Outstand | 46.68M | Perf Week | 4.40% |
| Market Cap | 2.02B | Forward P/E | — | EPS next Y | -2.28 | Insider Trans | -9.44% | Shs Float | 19.55M | Perf Month | 14.56% |
| Enterprise Value | 1.66B | PEG | — | EPS next Q | -0.41 | Short Float | 18.02% | Perf Quarter | 10.83% | ||
| Income | -25.00M | P/S | 20.37 | EPS this Y | — | Short Ratio | 9.18 | Perf Half Y | 74.05% | ||
| Sales | 99.00M | P/B | 5.21 | EPS next Y | — | ROA | -4.28% | Short Interest | 3.52M | Perf YTD | 54.95% |
| Book/sh | 8.29 | P/C | 5.42 | EPS next 5Y | — | ROE | -6.31% | 52W High | 51.10 -15.46% | Perf Year | 101.02% |
| Cash/sh | 7.97 | P/FCF | 19.02 | EPS past 3/5Y | — | ROIC | -8.89% | 52W Low | 17.55 146.15% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 99.57% | Volatility | 6.38% 6.31% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | 16.81 | EPS Y/Y TTM | — | Oper. Margin | -44.04% | ATR (14) | 2.42 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 4.99 | Sales Y/Y TTM | — | Profit Margin | -24.51% | RSI (14) | 61.37 | Recom | 1.89 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.99 | EPS Q/Q | 48.21% | SMA20 | 9.23% | Beta | 1.00 | Target Price | 50.40 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | — | SMA50 | 10.72% | Rel Volume | 1.20 | Prev Close | 44.00 |
| Employees | 123 | LT Debt/Eq | 0.05 | Earnings | Nov 09 | SMA200 | 34.33% | Avg Volume | 395.18K | Price | 43.20 |
| IPO Date | Oct 25, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 31.92% — | Net Debt/EBITDA | — | Volume | 475,332 | Change | -1.82% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-12-26 | Reiterated | HC Wainwright & Co. | Buy | $35 → $60 |
| Aug-11-26 | Reiterated | Raymond James | Strong Buy | $45 → $49 |
| Aug-11-26 | Reiterated | Stifel Nicolaus | $49 | |
| Aug-11-26 | Reiterated | Guggenheim | Buy | $45 → $51 |
| Jul-01-26 | Reiterated | Guggenheim | Buy | $52 → $45 |
| Jul-01-26 | Reiterated | Truist Securities | Buy | $34 → $43 |
| Jun-11-26 | Initiated | Guggenheim | Buy | $52 |
| Jun-08-26 | Reiterated | Raymond James | Strong Buy | $38 → $53 |
| Mar-10-26 | Reiterated | Cantor Fitzgerald | Overweight | $60 |
| Jan-20-26 | Reiterated | HC Wainwright & Co. | Buy | $35 |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | |
|---|---|---|---|---|---|
| Total Revenue | 99 | 46 | 1 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | |
| Gross Profit | 98 | 46 | 1 | 0 | |
| Selling, General and Administrative Excl. Other | 33 | 29 | 17 | 10 | |
| Research and Development | 120 | 98 | 65 | 36 | |
| Other Operating Expense | -11 | 0 | 0 | -48 | |
| Operating Income | -43 | -81 | -81 | 2 | |
| Interest Expense | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 21 | 32 | 9 | 3 | |
| Net Income Before Taxes | -23 | -49 | -72 | 5 | |
| Income Taxes | 1 | 0 | 0 | 1 | |
| Consolidated Net Income | -25 | -49 | -72 | 4 | |
| Net Income From Continuing Operations | -25 | -49 | -72 | 4 | |
| Net Income | -25 | -49 | -72 | 4 | |
| EPS (Recurring) | -0.54 | -1.10 | -1.93 | 0.03 | |
| EPS (Basic, Before Extraordinaries) | -0.54 | -1.10 | -1.93 | 0.03 | |
| EPS (Diluted) | -0.54 | -1.10 | -1.93 | 0.03 | |
| EBITDA | -39 | -47 | -71 | -45 | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | 19.64 | 26.67 | 847.30 | — | |
| Gross Margin | 98.99 | 100.00 | 100.00 | — | |
| Operating Margin | -43.43 | -176.09 | -8,100.00 | — | |
| Net Margin | -25.25 | -106.52 | -7,200.00 | — | |
| Shares Outstanding | 45 | 44 | 37 | 19 | |
| Market Capitalization | 1,944 | 1,227 | 847 | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bhatt Elizabeth | President and COO | Oct 15 '26 | Sale | 37.41 | 4,000 | 149,644 | 174,209 | Oct 19 |
| Bhatt Elizabeth | President and COO | Oct 15 '26 | Option Exercise | 6.81 | 4,000 | 27,240 | 178,209 | Oct 19 |
| Long Daniel D. | SVP, Drug Discovery | Sep 01 '26 | Sale | 37.83 | 3,333 | 126,078 | 96,412 | Sep 03 |
| Long Daniel D. | SVP, Drug Discovery | Sep 01 '26 | Option Exercise | 2.76 | 3,333 | 9,199 | 99,745 | Sep 03 |
| Third Rock Ventures V, L.P. | 10% Owner | Aug 12 '26 | Sale | 50.27 | 147,200 | 7,399,858 | 6,068,391 | Aug 14 |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Aug 12 '26 | Sale | 42.50 | 1,493,000 | 63,452,500 | 725,443 | Aug 14 |
| Bhatt Elizabeth | President and COO | Aug 11 '26 | Option Exercise | 5.79 | 25,000 | 144,658 | 199,209 | Aug 13 |
| Bhatt Elizabeth | President and COO | Aug 11 '26 | Sale | 44.00 | 25,000 | 1,100,000 | 174,209 | Aug 13 |
| Long Daniel D. | SVP, Drug Discovery | Aug 03 '26 | Option Exercise | 2.76 | 3,334 | 9,202 | 99,746 | Aug 05 |
| Long Daniel D. | SVP, Drug Discovery | Aug 03 '26 | Sale | 34.47 | 3,334 | 114,920 | 96,412 | Aug 05 |
| Bhatt Elizabeth | President and COO | Jul 15 '26 | Option Exercise | 6.81 | 4,000 | 27,240 | 178,209 | Jul 17 |
| Bhatt Elizabeth | President and COO | Jul 15 '26 | Sale | 33.99 | 4,000 | 135,974 | 174,209 | Jul 17 |
| Long Daniel D. | SVP, Drug Discovery | Jul 01 '26 | Option Exercise | 2.76 | 3,333 | 9,199 | 99,745 | Jul 02 |
| Long Daniel D. | SVP, Drug Discovery | Jul 01 '26 | Sale | 34.36 | 3,333 | 114,528 | 96,412 | Jul 02 |
| Shaikhly Samira | Chief People Officer | Jun 29 '26 | Option Exercise | 6.81 | 2,178 | 14,832 | 2,971 | Jun 30 |